BIO 2024: Enzene to Introduce New Division for Drug Discovery
Enzene's new division is dedicated to offering comprehensive discovery services from start to finish.
Enzene Biosciences has exciting news to share! They will be launching their Drug Discovery Division at the upcoming BIO 2024 International Convention in San Diego, Cali. The convention will take place from June 3–6, 2024. This is a significant step for Enzene Biosciences as they continue to expand their capabilities in the field of contract development and manufacturing. The CDMO's services will be expanded to cater to the biotech industry with the introduction of the new division. In addition, it will enhance the company's EnzeneX-equipped biologics manufacturing facility, which is set to launch in summer 2024 in New Jersey.
The new division will be situated at the company's Pune, India, facility and will feature a cutting-edge discovery laboratory. Our services encompass a comprehensive range of integrated discovery services. This includes antibody target validation, discovery, and engineering. We also offer reagent production, which spans from custom peptides and proteins to advanced modalities like plasmids, RNA, and exosomes. Additionally, we provide multi-platform assay services.
Enzene recently announced plans to open a new facility in New Jersey, set to be operational by July 2024. This facility will be Enzene's first site in the United States and will feature a fully connected continuous manufacturing platform. Our production capacity includes the ability to create intricate proteins using commonly used methods through Chinese hamster ovary and mammalian cell lines.
Our clients are seeking to collaborate with us earlier in the discovery phase to accelerate their progress towards IND and beyond, due to the global shortage of biology services. We expect a higher demand for these services in the upcoming year due to the increase in biotech funding. This will result in more targets entering the discovery phase, and contract R&D will enable them to progress multiple targets at the same time. Our company offers a range of services to our big pharma partners, including the ability to outsource non-core activities with ease. In addition to managing integrated programs, we prioritize flexibility to meet their specific needs. According to Himanshu Gadgil, CEO of Enzene Biosciences, there has been a significant demand for top-notch reagents and assay services that are essential in the field of drug discovery and development. This information was shared in a press release by the company.
In June of 2023, Choose New Jersey, a nonprofit economic development organization for the state of New Jersey, announced the opening of the New Jersey facility.
According to a press release, NJ Governor Phil Murphy expressed his enthusiasm for the growing partnership between New Jersey and India. He highlighted the progress made since the establishment of the New Jersey India Center, which aims to foster economic opportunities. The governor's remarks reflect the positive momentum in the relationship between the two entities. "I am delighted to welcome Enzene Biosciences and their growing global presence to New Jersey's thriving life sciences industry." Indian companies thrive in New Jersey due to its favorable business environment, skilled workforce, strategic location, supportive ecosystem for growth, and deep cultural ties.
In a press release issued in January 2024, Himanshu Gadgil, the CEO of Enzene Biosciences, highlighted the challenges faced by small biotech firms and start-ups in finding clinical-phase capacity. He emphasized the significance of these novel molecules, which are crucial in the development of life-saving drugs, most of which are found in the United States. Enzene Inc. has been launched in the US with the goal of creating access equity across the global healthcare ecosystem. Our mission is to establish a state-of-the-art manufacturing plant to cater to small and mid-sized biotech companies. We have efficiently identified, leased, and set up our first manufacturing facility in the [US] in a remarkably short period. We are confident that our EnzeneX technology platform and successful history in cost-effective biologics manufacturing will establish us as a preferred partner for biotech companies. We are committed to assisting them in bringing their promising molecules to market.
Source: Enzene Biosciences, Choose New Jersey
